Technical Analysis for XGN - Exagen Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Wide Bands | Range Expansion | 1.92% | |
Oversold Stochastic | Weakness | 1.92% | |
Calm After Storm | Range Contraction | 3.25% | |
Inside Day | Range Contraction | 3.25% | |
Wide Bands | Range Expansion | 3.25% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 20 hours ago |
Rose Above 10 DMA | about 20 hours ago |
10 DMA Resistance | about 21 hours ago |
Up 5% | about 21 hours ago |
Up 3% | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
Exagen Inc. Description
Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Disease Immunology Autoimmune Disease Bone Disorders Autoimmunity Rheumatoid Arthritis Blood Test Lupus Rheumatology Glutamate Fibromyalgia Systemic Lupus Erythematosus Erythema Methotrexate Scleroderma Sjögren's Syndrome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.9232 |
52 Week Low | 1.33 |
Average Volume | 38,859 |
200-Day Moving Average | 2.13 |
50-Day Moving Average | 1.93 |
20-Day Moving Average | 1.74 |
10-Day Moving Average | 1.59 |
Average True Range | 0.18 |
RSI (14) | 42.20 |
ADX | 16.84 |
+DI | 18.56 |
-DI | 22.11 |
Chandelier Exit (Long, 3 ATRs) | 1.76 |
Chandelier Exit (Short, 3 ATRs) | 1.95 |
Upper Bollinger Bands | 2.08 |
Lower Bollinger Band | 1.40 |
Percent B (%b) | 0.28 |
BandWidth | 39.37 |
MACD Line | -0.12 |
MACD Signal Line | -0.11 |
MACD Histogram | -0.0131 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.77 | ||||
Resistance 3 (R3) | 1.77 | 1.71 | 1.74 | ||
Resistance 2 (R2) | 1.71 | 1.66 | 1.71 | 1.73 | |
Resistance 1 (R1) | 1.65 | 1.63 | 1.68 | 1.65 | 1.72 |
Pivot Point | 1.59 | 1.59 | 1.60 | 1.59 | 1.59 |
Support 1 (S1) | 1.53 | 1.54 | 1.56 | 1.53 | 1.46 |
Support 2 (S2) | 1.47 | 1.52 | 1.47 | 1.45 | |
Support 3 (S3) | 1.41 | 1.47 | 1.44 | ||
Support 4 (S4) | 1.41 |